BrainStorm

Company Overview

Snapshot

Founded in January 2000, BrainStorm operates with 11–50 employees and has raised a total of $67.13 million across 17 funding rounds from 3 investors. In October 2003, the company went public on NASDAQ.

Business overview

BrainStorm Cell Therapeutics is a biotechnology company focused on developing autologous stem cell therapeutics for neurodegenerative diseases, specifically Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). The company's core technology, NurOwn®, involves transforming mesenchymal stem cells into neurotrophic factor-secreting cells to deliver growth factors to affected areas. BrainStorm serves the healthcare and life sciences sectors, targeting patients and providers within the biotechnology and pharmaceutical industries.

Strategic signal

In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment to prioritize the development of NurOwn® for ALS, following a period of regulatory discussions. This move indicates a focused effort to streamline operations and allocate resources more efficiently towards critical clinical trials and regulatory submissions, signaling to investors a clear strategic direction and commitment to advancing their lead therapeutic candidate despite previous setbacks.

Company Intelligence Q&A

What is BrainStorm's primary therapeutic focus?

BrainStorm Cell Therapeutics primarily focuses on developing autologous stem cell therapeutics for neurodegenerative disorders, particularly Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS).

What was the outcome of the FDA Advisory Committee meeting regarding NurOwn® for ALS?

In September 2023, FDA advisers voted against the experimental ALS treatment NurOwn®, leading to a halt in BrainStorm Cell Therapeutics' stock trading.

When did BrainStorm Cell Therapeutics announce its strategic realignment?

In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment to prioritize NurOwn® for the treatment of ALS.

What was the outcome of BrainStorm's meeting with the FDA in November 2023?

In November 2023, BrainStorm Cell Therapeutics announced an in-person meeting with the FDA to discuss a confirmatory Phase 3 trial for NurOwn® in ALS.

Did BrainStorm Cell Therapeutics regain compliance with Nasdaq listing requirements?

In October 2024, BrainStorm Cell Therapeutics regained compliance with the Nasdaq minimum bid price requirement.